Tell your friends about this item:
The Timing of Toxicological Studies to Support Clinical Trials C Parkinson 1994 edition
The Timing of Toxicological Studies to Support Clinical Trials
C Parkinson
Senior clinicians, pharmacologists and toxicologists from companies in Europe, the USA and Japan met in May 1994 to discuss a scientific rationale for the conduct of toxicity studies to support the clinical development of new medicines, and to begin to work towards an industry consensus.
Marc Notes: Includes bibliographical references and index. Table of Contents: Section I: Introduction and Presentations.- 1 The application of toxicological investigations in the safe development of medicines.- 2 Review of international recommendations on animal toxicity studies and their relation to clinical exposure.- 3 International survey on the timing of toxicity studies in relation to clinical trials.- 4 Considerations for implementing a toxicity testing strategy.- Section II: Personal Views.- 5 Phase I clinical trials: what is the minimum preclinical package necessary for initiating single-dose studies in man? a toxicologist s opinion.- 6 Phase I clinical trials: what is the minimum preclinical package necessary for initiating single-dose studies in man? a clinical pharmacologist s opinion.- 7 The duration of toxicity studies required to support repeated dosing in clinical investigation a toxicologist s opinion.- 8 The duration of toxicity studies required to support repeated dosing in clinical investigation a clinician s opinion.- 9 Reproductive and developmental toxicity studies required to support the inclusion of women and children in clinical trials a toxicologist s opinion.- Section III: Proposals and the Way Forward.- 10 The minimum non-clinical package for initiating Phase I clinical trials.- 11 The duration of toxicity studies to support repeated dosing in clinical investigation.- 12 The timing of reproductive toxicity studies in relation to clinical trials.- The way forward.- 14 Input to ICH.- Meeting participants."